Retatrutide — wholesale 10-vial kits

Research context

Retatrutide is a so-called triple agonist: one peptide chain designed to engage three class B G-protein-coupled receptors that are normally activated by three separate gut and pancreatic hormones. It is built on an incretin-like backbone with non-coded amino acids and a fatty-acid side chain that promotes albumin binding, which extends its half-life in experimental systems well beyond that of the native hormones.

Origin and molecular design. Retatrutide was discovered at Eli Lilly under the code LY3437943, and its discovery-to-proof-of-concept work was published in Cell Metabolism in 2022. The FDA Global Substance Registration System (GSRS) record describes a 39-residue, C-terminally amidated chain carrying three non-coded residues: α-aminoisobutyric acid (Aib) at positions 2 and 20 and α-methyl-L-leucine at position 13. Aib2 blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates native GIP and GLP-1, and α,α-disubstituted residues of this kind favor a helical conformation and resist proteolysis. Lysine 17 carries a C20 fatty diacid attached through a γ-glutamic acid / AEEA linker, which is the albumin-binding element. The C-terminal GPSSGAPPPS segment is the same tail found in exendin-4 and in tirzepatide.

In receptor pharmacology, retatrutide is studied for its relative potency at each target. In Lilly's in-vitro characterization it showed more activity at the GIP receptor than at the GLP-1 and glucagon receptors, with the latter two roughly balanced. In obese mice, the glucagon-receptor component added an increase in energy expenditure to the reduction in calorie intake driven by GIP- and GLP-1-receptor agonism. That profile makes it a useful tool for comparing balanced and biased multi-receptor agonism in cAMP accumulation, β-arrestin recruitment and receptor-internalization assays, normally in cell lines that each express a single human receptor so the contribution of every target can be read separately. Analytical groups also use it as a reference material when developing LC-MS methods for long-acting lipidated peptides.

U.S. regulatory status: retatrutide is investigational and has not been approved by the FDA. Lilly's Phase 2 results were published in the New England Journal of Medicine (2023) and Nature Medicine (2024), and the first report from the Phase 3 TRIUMPH program, TRIUMPH-1, appeared in the New England Journal of Medicine in 2026 (see sources below). The material sold here is a research reference compound, not a drug product, and is supplied only for in-vitro, analytical and preclinical laboratory research.

Because retatrutide is lipidated and contains non-standard residues, its identity is best confirmed by an exact mass from LC-MS rather than by HPLC purity alone. Every lot we sell carries a lot-specific Certificate of Analysis that reports both.

Typical study designs compare retatrutide head-to-head with tirzepatide (GIP / GLP-1) and with GLP-1 / glucagon dual agonists such as survodutide and mazdutide, so that the contribution of each receptor can be separated. Groups running those comparisons usually order several incretin compounds at once, which is why mixed-compound kits count toward the same wholesale tier.

Research areas

• GLP-1 / GIP / glucagon receptor binding assays
• Multi-receptor agonism and signaling bias (cAMP, β-arrestin)
• Incretin receptor pharmacology in cell-based models
• Glucagon-receptor contribution to energy expenditure in rodent models
• LC-MS method development for lipidated peptides
• Comparative studies against dual and single incretin agonists

U.S. regulatory status of the compound (as an active ingredient): Investigational peptide, not yet approved by the FDA. The material sold here is a research reference chemical, not a drug product.

Handling and storage

• Store lyophilized vials at −20 °C, sealed, protected from light and moisture.
• Let the vial reach room temperature before opening to limit condensation on the powder.
• Lipidated peptides can adsorb to plastics; low-binding tubes and a carrier protein in the assay buffer are common lab practice.
• Aliquot reconstituted material and freeze once; avoid repeated freeze–thaw.